BridgeMD
New treatment option for Cardiogenic Shock
Official title Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO
ClinicalTrials.gov ID: NCT06792643
What this study is testing
What is Cangrelor?
Cangrelor is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for cardiogenic shock.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)/ cardiac arrest (CA) who undergo percutaneous coronary intervention (PCI). The investigators plan to achieve this by starting cangrelor on top of systemic anticoagulation with bivalirudin at a low dose, regularly monitoring platelet function, and adjusting the dose based on the results of platelet function assay (Multiplate®) to guarantee effective platelet P2Y12 pathway inhibition to achieve optimal platelet inhibition.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male or female patients aged ≥18 years;
- ACS-related CS/CA patients undergoing PCI (either with or without stent implantation) and needing VA-ECMO support;
- Patients who received pre-hospital aspirin intravenous loading dose or patients naïve to any anti-thrombotic agent;
- Written informed consent
You likely can't join if
- Overt uncontrollable bleeding;
- Suspected intra-cranial haemorrhage;
- Patients who received any dose of any oral P2Y12-inhibitors;
- Patients with known history of stroke or Transient Ischaemic Attack (TIA);
- Patients with known hypersensitivity to the active substance (cangrelor) or to any of its excipients;
- Pregnancy.
The study team makes the final eligibility decision.
Where it's taking place
- Milan, Italy, Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Milan, Italy, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.